| ￥4100 | |
| Z06222-100 | |
|
|
|
|
|
|
|
|
|
| Species | Mouse | ||||
| Protein Construction |
|
||||
| Purity |
> 95% as determined by BisTris PAGE > 90% as determined by HPLC |
||||
| Endotoxin Level | Less than 1EU per μg by the LAL method. | ||||
| Expression System | HEK293 | ||||
| Theoretical Molecular Weight | 109.80 kDa (ITGA2B) and 80.80 kDa (ITGB3) | ||||
| Apparent Molecular Weight | Due to glycosylation, the protein migrates to 90-113 kDa based on Bis-Tris PAGE result. | ||||
| Formulation | Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). | ||||
| Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. | ||||
| Storage & Stability | Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
The purity of Integrin alpha 2B beta 3 (ITGA2B&ITGB3) Heterodimer, His, Mouse is greater than 90% as determined by SEC-HPLC. »
Integrin alpha 2B beta 3 (ITGA2B&ITGB3) Heterodimer, His, Mouse on Bis-Tris PAGE under reduced condition. The purity is greater than 95%. »
| Target Background | Glanzmann thrombasthenia (GT) is characterized by mucocutaneous bleeding due to platelets that fail to aggregate in response to physiologic stimuli. GT, a rare inherited disease, is caused by quantitative or qualitative deficiencies of αIIbβ3, an integrin receptor for adhesive proteins. Coded by the ITGA2B and ITGB3 genes, αIIbβ3 mediates platelet-to-platelet attachment, aggregation and clot retraction. |
| Synonyms | α2Bβ3; ITGA2B&ITGB3; ITGA2B; ITGB3 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
